Results 31 to 40 of about 42,337 (292)

Genomic analysis of bone marrow failure and myelodysplastic syndromes reveals phenotypic and diagnostic complexity

Haematologica, 2015
Accurate and timely diagnosis of inherited bone marrow failure and inherited myelodysplastic syndromes is essential to guide clinical management. Distinguishing inherited from acquired bone marrow failure/myelodysplastic syndrome poses a significant ...
Michael Y. Zhang, Siobán B. Keel, Tom Walsh, Ming K. Lee, Suleyman Gulsuner, Amanda C. Watts, Colin C. Pritchard, Stephen J. Salipante, Michael R. Jeng, Inga Hofmann, David A. Williams, Mark D. Fleming, Janis L. Abkowitz, Mary-Claire King, Akiko Shimamura   +14 more
doaj   +1 more source

Severely impaired terminal erythroid differentiation as an independent prognostic marker in myelodysplastic syndromes

Blood Advances, 2018
: Anemia is the defining feature in most patients with myelodysplastic syndromes (MDS), yet defects in erythropoiesis have not been well characterized. We examined freshly obtained bone marrow (BM) samples for stage-specific abnormalities during terminal
Abdullah Mahmood Ali, Yumin Huang, Ronald Feitosa Pinheiro, Fumin Xue, Jingping Hu, Nicholas Iverson, Daniela Hoehn, Diego Coutinho, Jehanzeb Kayani, Brian Chernak, Joseph Lane, Christopher Hillyer, Naomi Galili, Joseph Jurcic, Narla Mohandas, Xiuli An, Azra Raza   +16 more
doaj  

Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells

Haematologica, 2011
Background The World Health Organization separates acute erythroid leukemia (erythropoiesis in ≥50% of nucleated bone marrow cells; ≥20% myeloblasts of non-erythroid cells) from other entities with increased erythropoiesis – acute myeloid leukemia with ...
Ulrike Bacher, Claudia Haferlach, Tamara Alpermann, Wolfgang Kern, Susanne Schnittger, Torsten Haferlach   +5 more
doaj   +1 more source

PTK2 and PTPN11 expression in myelodysplastic syndromes

Clinics, 2013
OBJECTIVE: The aim of this study was to evaluate the expression of protein tyrosine kinase 2 and protein tyrosine phosphatase non-receptor type 11, which respectively encode focal adhesion kinase protein and src homology 2 domain-containing protein ...
Mariana Lazarini, Joao Agostinho Machado-Neto, Leticia Frohlich Archangelo, Bruna Fernandes Mendes-Silva, Carolina Louzao Bigarella, Fabiola Traina, Sara Teresinha Olalla Saad   +6 more
doaj   +1 more source

Randomization in phase II trials: No exemption based on sample size

British Journal of Clinical Pharmacology, EarlyView.
Conducting randomized clinical trials (RCTs) is challenging. For this reason, in earlier phases of drug development and rare diseases with limited sample sizes, there is a tendency to omit control groups and to replace them with historical information for perceived feasibility arguments.
Theodor Framke, Gernot Beutel, Arnold Ganser, Armin Koch, Anika Großhennig   +4 more
wiley   +1 more source

The role of magnetic resonance imaging in the evaluation of transfusional iron overload in myelodysplastic syndromes

Revista Brasileira de Hematologia e Hemoterapia, 2015
Myelodysplastic syndromes represent a group of heterogeneous hematopoietic neoplasms derived from an abnormal multipotent progenitor cell, characterized by a hyperproliferative bone marrow, dysplasia of the cellular hemopoietic elements and ineffective ...
Emmanouil Petrou, Sophie Mavrogeni, Vasiliki Karali, Genovefa Kolovou, Marie-Christine Kyrtsonis, Petros P. Sfikakis, Panayiotis Panayiotidis   +6 more
doaj   +1 more source

Neutrophils in cancer: At the crucial crossroads of anti‐tumor and pro‐tumor

Cancer Communications, EarlyView.
Abstract Neutrophils are important components of the immune system and play a key role in defending against pathogenic infections and responding to inflammatory cues, including cancer. Their dysregulation indicates potential disease risk factors. However, their functional importance in disease progression has often been underestimated due to their ...
Wenpeng Cai, Tao Fan, Chu Xiao, Ziqin Deng, Yixiao Liu, Chunxiang Li, Jie He   +6 more
wiley   +1 more source

Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes

Haematologica, 2017
Accumulating evidence implicates innate immune activation in the pathobiology of myelodysplastic syndromes. A key myeloid-related inflammatory protein, S100A9, serves as a Toll-like receptor ligand regulating tumor necrosis factor-α and interleukin-1β ...
Thomas Cluzeau, Kathy L. McGraw, Brittany Irvine, Erico Masala, Lionel Ades, Ashley A. Basiorka, Jaroslaw Maciejewski, Patrick Auberger, Sheng Wei, Pierre Fenaux, Valeria Santini, Alan List   +11 more
doaj   +1 more source

Combined Immediate‐Release and Extended‐Release Formulation of Sodium Valproate Provides Stable Plasma Levels for Inhibition of Histone Deacetylation

Clinical Pharmacology in Drug Development, EarlyView.
Abstract A modified controlled‐release sodium valproate formulation (VAL001, test) was compared with an approved enteric‐coated tablet formulation (Absenor, reference). Pharmacokinetics and safety/tolerability were evaluated in healthy subjects to bridge with positive efficacy results from an early‐phase patient trial of valproate in combination with ...
Nikhil Ahuja, Susanna Kääriäinen, Zsófia Lovró, Mia Lundblad, Kristina Drott, Elsa Lilienberg, Marica T. Engström, Karla Saukkonen, Mika Scheinin   +8 more
wiley   +1 more source

Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes

Haematologica, 2012
Background There are limited reports of thrombosis among myelodysplastic syndrome patients exposed to erythropoiesis stimulating agents. It is not clear whether erythropoiesis stimulating agents are associated with an increased risk of thrombosis in ...
Sheila Weiss Smith, Masayo Sato, Steven D. Gore, Maria R. Baer, Xuehua Ke, Diane McNally, Amy Davidoff   +6 more
doaj   +1 more source